ASLAN PHARMACEUTICALS ADR REP 5 (ASLN) Sets New 12-Month Low at $4.20
ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) shares hit a new 52-week low during trading on Thursday . The company traded as low as $4.20 and last traded at $4.90, with a volume of 836 shares trading hands. The stock had previously closed at $5.00.
A number of research analysts recently commented on ASLN shares. Zacks Investment Research raised shares of ASLAN PHARMACEUTICALS ADR REP 5 from a “sell” rating to a “hold” rating in a research report on Friday, November 2nd. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Tuesday, August 21st. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $10.94.
ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) last posted its earnings results on Thursday, November 8th. The company reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.27. As a group, equities analysts predict that ASLAN PHARMACEUTICALS ADR REP 5 will post -1.41 earnings per share for the current year.
About ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN)
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in developing therapeutics for global markets. It targets diseases that are highly prevalent in Asia, and orphan indications in the United States and Europe. The company's product pipeline includes Varlitinib, a reversible small molecule pan-human epidermal growth factor receptor inhibitor that is being studied in global pivotal trials (TreeTopp) for biliary tract cancer, and conducting Phase 2/3 clinical trials for gastric cancer, as well as testing in a single-arm pivotal clinical trial in biliary tract cancer in China.
See Also: 52-Week High/Low
Receive News & Ratings for ASLAN PHARMACEUTICALS ADR REP 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEUTICALS ADR REP 5 and related companies with MarketBeat.com's FREE daily email newsletter.